Haleon (LON:HLN – Get Free Report) had its target price lowered by equities researchers at Deutsche Bank Aktiengesellschaft from GBX 335 to GBX 320 in a report issued on Wednesday, Digital Look reports. The brokerage presently has a “sell” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential downside of 4.36% from the stock’s current price.
Other equities analysts have also recently issued reports about the stock. Berenberg Bank upped their price objective on shares of Haleon from GBX 512 to GBX 514 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. decreased their target price on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research note on Thursday, June 25th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 400 price target on shares of Haleon in a report on Friday, July 31st. Finally, Royal Bank Of Canada upped their price target on shares of Haleon from GBX 370 to GBX 390 and gave the stock a “sector perform” rating in a report on Tuesday, August 11th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of GBX 396.50.
Read Our Latest Stock Analysis on HLN
Haleon Stock Performance
Haleon (LON:HLN – Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 14.55% and a return on equity of 9.89%. As a group, analysts expect that Haleon will post 19.5033282 earnings per share for the current fiscal year.
Haleon Company Profile
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Read More
- Five stocks we like better than Haleon
- PayPal’s Takeover Story Ended, But Its Turnaround Story Didn’t
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
